Ran Chu

Dr. Ran Chu

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2021 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
JLJunting Li
Junting Li
RCRan Chu
Ran Chu
ZCZhongshao Chen
Zhongshao Chen
JMJinyu Meng
Jinyu Meng
SYShu Yao
Shu Yao
BKBeihua Kong
Beihua Kong

21 July 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
RCRan Chu
Ran Chu
WCWei Chen
Wei Chen
GSGuangmin Song
Guangmin Song
SYShu Yao
Shu Yao
LXLin Xie
Lin Xie
BKBeihua Kong
Beihua Kong
Background: Women with congenital heart disease are considered at high risk for adverse events. Therefore, we aim to establish 2 prediction models for mothers and their offspring, which can predict the risk of adverse events occurred in pregnant women with congenital heart disease. Methods and Results: A total of 318 pregnant women with congenital heart disease were included; 213 women were divided into the development cohort, and 105 women were divided into the validation cohort. Least absolute shrinkage and selection operator was used for predictor selection. After validation, multivariate logistic regression analysis was used to develop the model. Machine learning algorithms (support vector machine, random forest, AdaBoost, decision tree, k‐nearest neighbor, naïve Bayes, and multilayer perceptron) were used to further verify the predictive ability of the model. Forty‐one (12.9%) women experienced adverse maternal events, and 93 (29.2%) neonates experienced adverse neonatal events. Seven high‐risk factors were discovered in the maternal model, including New York Heart Association class, Eisenmenger syndrome, pulmonary hypertension, left ventricular ejection fraction, sinus tachycardia, arterial blood oxygen saturation, and pregnancy duration. The machine learning–based algorithms showed that the maternal model had an accuracy of 0.76 to 0.86 (area under the receiver operating characteristic curve=0.74–0.87) in the development cohort, and 0.72 to 0.86 (area under the receiver operating characteristic curve=0.68–0.80) in the validation cohort. Three high‐risk factors were discovered in the neonatal model, including Eisenmenger syndrome, preeclampsia, and arterial blood oxygen saturation. The machine learning–based algorithms showed that the neonatal model had an accuracy of 0.75 to 0.80 (area under the receiver operating characteristic curve=0.71–0.77) in the development cohort, and 0.72 to 0.79 (area under the receiver operating characteristic curve=0.69–0.76) in the validation cohort. Conclusions: Two prenatal risk assessment models for both adverse maternal and neonatal events were established, which might assist clinicians in tailoring precise management and therapy in pregnant women with congenital heart disease.

16 September 2021 in The Oncologist
Verified
Journal Article
Open access
PDF file
RCRan Chu
Ran Chu
YZYue Zhang
Yue Zhang
Qiao XuQiao Xu
Qiao Xu
LXLin Xie
Lin Xie
WCWei Chen
Wei Chen
KSKun Song
Kun Song
Background: Adjuvant therapy for patients with cervical cancer (CC) with intermediate-risk factors remains controversial. The objectives of the present study are to assess the prognoses of patients with early-stage CC with pathological intermediate-risk factors and to provide a reference for adjuvant therapy choice. Materials and Methods: This retrospective study included 481 patients with stage IB–IIA CC. Cox proportional hazards regression analysis, machine learning (ML) algorithms, Kaplan-Meier analysis, and the area under the receiver operating characteristic curve (AUC) were used to develop and validate prediction models for disease-free survival (DFS) and overall survival (OS). Results: A total of 35 (7.3%) patients experienced recurrence, and 20 (4.2%) patients died. Two prediction models were built for DFS and OS using clinical information, including age, lymphovascular space invasion, stromal invasion, tumor size, and adjuvant treatment. Patients were divided into high-risk or low-risk groups according to the risk score cutoff value. The Kaplan-Meier analysis showed significant differences in DFS (p = .001) and OS (p = .011) between the two risk groups. In the traditional Sedlis criteria groups, there were no significant differences in DFS or OS (p > .05). In the ML-based validation, the best AUCs of DFS at 2 and 5 years were 0.69/0.69, and the best AUCs of OS at 2 and 5 years were 0.88/0.63. Conclusion: Two prognostic assessment models were successfully established, and risk grouping stratified the prognostic risk of patients with CC with pathological intermediate-risk factors. Evaluation of long-term survival will be needed to corroborate these findings. Implications for Practice: The Sedlis criteria are intermediate-risk factors used to guide postoperative adjuvant treatment in patients with cervical cancer. However, for patients meeting the Sedlis criteria, the choice of adjuvant therapy remains controversial. This study developed two prognostic models based on pathological intermediate-risk factors. According to the risk score obtained by the prediction model, patients can be further divided into groups with high or low risk of recurrence and death. The prognostic models developed in this study can be used in clinical practice to stratify prognostic risk and provide more individualized adjuvant therapy choices to patients with early-stage cervical cancer.

1 January 2023 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
RCRan Chu
Ran Chu
PLPenglin Liu
Penglin Liu
JCJingying Chen
Jingying Chen
XCXiaodong Cheng
Xiaodong Cheng
KLKezhen Li
Kezhen Li
KSKun Song
Kun Song
Chu R, et al. J Gynecol Oncol. 2022 Nov;34(2):e12. https://doi.org/10.3802/jgo.2023.34.e12

12 February 2024 in Journal of Anesthesia
Verified
Journal Article
Closed access
PDF file
CLChenmian Liu
Chenmian Liu
RCRan Chu
Ran Chu
NSNingning Song
Ningning Song
QYQiuhong Yang
Qiuhong Yang
XSXiao Song
Xiao Song
YMYuyan Ma
Yuyan Ma

29 January 2024 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
YLYan Liu
Yan Liu
FGFeng Geng
Feng Geng
HZHongyang Zhang
Hongyang Zhang
JXJing Xue
Jing Xue
RCRan Chu
Ran Chu
Background: Ovarian clear cell carcinoma (OCCC) shares treatment strategies with epithelial ovarian cancer (EOC). Due to OCCC's rarity, there's a lack of prospective studies on its surgery, resulting in heterogeneous and limited existing data. This study aims to clarify the prognostic significance of lymphadenectomy in OCCC patients. Methods: We systematically searched Web of Science, Scopus, PubMed, and Google Scholar until July 2023 for studies investigating lymphadenectomy's effects on OCCC patients. We calculated pooled hazard ratios (HR) with 95% confidence intervals (CI). This study is registered in PROSPERO (CRD42021270460). Results: Among 444 screened articles, seven studies (2883 women) met inclusion criteria. Our analysis revealed that lymphadenectomy significantly improved disease-specific survival (DSS) (HR = 0.76, 95%CI = 0.60–0.95, P = 0.02) and disease-free survival (DFS) (HR = 0.58, 95%CI = 0.34–0.99, P = 0.05). However, it did not significantly affect overall survival (OS) (HR = 0.80, 95%CI = 0.60–1.06, P = 0.12) or progression-free survival (PFS) (HR = 0.95, 95%CI = 0.64–1.42, P = 0.79). Notably, some earlier studies reported no survival benefit, warranting cautious interpretation. Conclusion: Lymphadenectomy does not significantly enhance OS and PFS for OCCC but does improve DFS and DSS. Tailoring treatment to individual patient profiles is imperative for optimal outcomes. Precise preoperative or intraoperative lymph node metastasis detection is essential for identifying candidates benefiting from lymphadenectomy. Collaborative international efforts and an OCCC database are pivotal for refining future treatment strategies.